According to reports, the vaccine developed by Oxford University and AstraZeneca in the United Kingdom showed it was "safe, well tolerated and immunogenic", the vaccine according to Lancet also showed single dose elicited both "humoral and cellular responses against the virus".
Bangladesh's state medical research agency has approved a third-phase trial of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd, as infections rise in the densely populated South Asian country. The immune responses remained strong for at least 56 days. T-cells are immune responses by the body against the foreign virus, and are crucial for maintaining protection against the virus for longer periods of time.
Cadila, among India's top 10 drugmakers by revenue, is also planning to produce the drug remdesivir that is in high demand globally after it showed promise in treating severe patients with COVID-19, the disease caused by the novel coronavirus.
"The Phase I/II data for our coronavirus vaccine shows that the vaccine did not lead to any unexpected reactions and had a similar safety profile to previous vaccines of this type".
The fast pace of the vaccine effort has been cheered by officials around the world, however health experts warn that much remains unknown about the virus, and more testing is needed to understand how to offer people long-term protection against COVID-19, clinically known as SARS-CoV-2.
Chinese researchers also published a study Monday in The Lancet of their own experimental coronavirus vaccine.
Scientists in Oxford released the results of Phase 1 of the coronavirus vaccine human trials.
Historic Ronaldo puts Juve on brink of ninth straight Serie A title
Just one point had separated Juventus from Lazio when Serie A returned last month following the three-month coronavirus lockdown. Cristiano Ronaldo may be 35 years old but the Portuguese superstar continues to live up to the idea that age is just a number.
The company is expected to begin trials in Japan in August as the world waits for a vaccine to stop the pandemic. As part of CSIRO's preclinical study of Oxford's vaccine candidate, our scientists evaluated the efficacy of one versus two doses as well as administration of the vaccine via a nasal delivery and/or an intramuscular injection.
About 1,000 people ages 18 to 55 were involved in the Phase 2 Oxford trials, with about half of the subjects receiving the experimental vaccine.
The vaccine is being developed by the pharmaceutical company AstraZeneca in partnership with Oxford University.
Several research organisations from across the country and outside have been eagerly waiting for such a unit in this part of the country to generate evidence in clinical research, based on factors such as local population, Rao said.
The trials are the result of a cooperation partnership between Abu Dhabi-based G42 Healthcare, now at the forefront of the battle against Covid-19 in the UAE, and Sinopharm's China National Biotec Group (CNBG).
As per the results, the vaccine boosted T cell and antibody immunity.
Others like Mynvax and Biological E are also working to develop vaccines for COVID-19.